P3-027Liver Cirrhosis Associated With Paclitaxel and Bevacizumab Combination Therapy in a Metastatic Breast Cancer Patient

Annals of Oncology - United Kingdom
doi 10.1093/annonc/mdy375.058
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

A Phase II Trial of Erlotinib in Combination With Bevacizumab in Patients With Metastatic Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2008English

The Results of a Study of Chemotherapy With Bevacizumab, Oxaliplatin and Paclitaxel in Patients With Metastatic Triple Negative Breast Cancer

Malignant tumours
2017English

Effect of Lipodox in Combination With Bevacizumab in a Patient With a Metastatic Malignant Phyllodes Breast Tumor: A Case Report

Oncology Letters
Cancer ResearchOncology
2017English

Combination Chemotherapy in Metastatic Breast Cancer

BMJ
1977English

Combination Chemotherapy in Metastatic Breast Cancer

InPharma
1977English

Toxicity of Locoregional Radiotherapy in Combination With Bevacizumab in Patients With Non-Metastatic Breast Cancer (TOLERAB): Final Long-Term Evaluation

PLoS ONE
Multidisciplinary
2019English

Quality-Adjusted Survival With Nab -Paclitaxel vs Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis

Clinical Breast Cancer
Cancer ResearchOncology
2018English

Combination Cisplatin‐Epirubicin‐Paclitaxel Therapy for Metastatic Extramammary Paget's Disease

Oncologist
Cancer ResearchMedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy